Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.55 |
| ▸ | GABRP | O00591 | 2/20 | 0.55 |
| ▸ | GABRD | O14764 | 2/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.55 |
| ▸ | GABRE | P78334 | 2/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.55 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.55 |
| ▸ | NNMT | P40261 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromoethane SCHEMBL28771018 | 0.92 | GABRP (0.47) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL31188361 | 0.87 | MKNK1 (0.59) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL9834746 | 0.81 | HDAC1 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL29826707 | 0.80 | MAPK1 (0.65) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL31532 | 0.80 | MAPK1 (0.65) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1462391 | 0.79 | CA12 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL2571730 | 0.79 | GAA (0.57) | SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL646488 | 0.79 | CA12 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30812042 | 0.79 | CA12 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL17166085 | 0.79 | CA12 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116323601-B | 2- (3-Pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | AGOMAB SPAIN S.L.U. (ES) | 2026-03-17 | — | — | US | disclosed |
| CN-117343004-A | Preparation method of 2-aminopyridine compound | 易简和成(江苏)医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230373966-A1 | 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | AGOMAB SPAIN S.L.U. (ES) | 2023-11-23 | — | — | US | disclosed |
| EP-4222149-A1 | 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | AgomAb Spain, S.L.U. (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-116323601-A | 2- (3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113831337-B | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2022069509-A1 | 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | ORIGO BIOPHARMA, S.L. (ES) | 2022-04-07 | — | — | WO | disclosed |
| CN-113831337-A | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2021-12-24 | — | — | CN | disclosed |
| WO-2021188944-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| CN-103987696-A | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO | 2014-08-13 | — | — | CN | disclosed |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| WO-2012020357-A1 | ACETAMIDE COMPOUNDS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS LTD. (IN) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020357-A1 | ACETAMIDE COMPOUNDS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS LTD. (IN) | 2012-02-16 | — | — | WO | disclosed |
| CN-1460097-A | NF-kB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY SEIYAKU CO LTD (JP) | 2003-12-03 | — | — | CN | disclosed |
| US-4141977-A | Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds | YU RUEY J | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | TGFBR1, TGFBR2, ACVR1 | GABRA1 377/4885GABRG2 998/4885GABRB3 283/4885 |
| US-20230373966-A1 | 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | ACVR1, ACVRL1, TGFBR2 | GABRA1 1756/4885GABRG2 2963/4885GABRB3 2001/4885 |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | GCK, GCKR, ALDOA | GABRA1 2515/4885GABRG2 2915/4885GABRB3 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.